Pompilio, G., A. Morabito, D. L. Cortinovis, and D. Integlia. “Budget Impact Analysis of Afatinib for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) Patients With Uncommon EGFR Mutations”. Global and Regional Health Technology Assessment, vol. 9, no. 1, Jan. 2022, pp. 22-29, doi:10.33393/grhta.2022.2351.